

PRESS RELEASE

Artificial intelligence (AI) guided management strategies for male urethral stricture; MediNippon Healthcare ties up with PageLightPrime



Dr. Preethy (Left), MediNippon Healthcare with Dr. Senthil Kumar (R & D Coordinator, GN Corporation, Japan (Centre-Left)) exchanging MoU with Ms. Chandra Jeganathan (Director, PageLightPrime (Centre-Right)). To the extreme right is Mr. Viji Anbumani (AI expert & Founder, PageLightPrime, USA)

Chennai, February 20, 2026; Male urethral stricture disease (USD) which occurs in 229–627 per 100,000 men globally, of all ages remains a nagging problem due to its unpredictable recurrence and the lack of definitive guidance on the most suitable treatment approach. Having earlier developed novel hybrid cell therapies for urethral stricture such as the BEES-HAUS (Buccal epithelium Expanded and Encapsulated in Scaffold-Hybrid Approach to Urethral Stricture) jointly with GN Corporation, Japan, who were instrumental in the tech-transfer of this cell therapy technology from India to Japan successfully and with recent literature evidence pointing to several biomarkers with wide range of variabilities, considering the need for a meta-analysis to arrive at prediction of the disease course and to help choose the right treatment approach, Medinippon Healthcare, India has signed a MOU with PageLightPrime, an AI solutions company based in Singapore and India.

Male USD which usually starts as a small segment stenosis, despite various treatment approaches like balloon dilatation and DVIU for the initial management, has a high recurrence rate. While buccal mucosal graft (BMG)-plasty is the gold standard, learning curve is an issue and is not available in all urology centers. [Further, worldwide, there is a big difference in the outcome of BMG Plasty between centers.](#) To arrive at a suitable management strategy, which should give long duration of recurrence-free good quality of life to patients, a detailed evaluation of the patient's biomarkers associated with spongiofibrosis leading to stricture recurrence is the need of the hour. PageLightPrime having expertise in AI based analysis of large data sets with current strength in providing AI based solutions in legal and allied specialties, is foraying into healthcare through their Singapore and Indian teams, whereas Dr. Suryaprakash, Urologist will advise on the criteria of clinical significance to be evaluated and GN Corporation, the parent company of Medinippon will bring in their inter-disciplinary research expertise in healthcare.

Based on mutual strengths an AI tool called "[HAUS SCORE](#)" is being developed and once some headway into scores of prediction and management strategies is arrived at, PageLightPrime USA will also join the efforts to make this a globally accessible database in the future.

Contacts:

MediNippon Healthcare Pvt. Ltd,

mail@medinippon.jp

Mobile: +91-9444927694